Troubled gene therapy player bluebird sold for a song
12 years after going public, beleaguered gene therapy company bluebird bio will be sold to private equity groups Carlyle and SK Capital Partners for around $29 million – less than half its current value and a fraction of its peak market cap of around $9 billion.
What's Going On With Gene Therapy Company Bluebird Bio Stock Today?
Bluebird Bio, Inc. (NASDAQ:BLUE), on Friday, entered into a definitive agreement to be acquired by global investment firms Carlyle Group Inc. (NASDAQ:CG) and SK Capital Partners. The agreement, which also includes a team of biotech executives,
Beqvez was Pfizer's first gene therapy, stemming from an alliance with Spark Therapeutics (now part of Roche) more than a ...
The pioneering gene therapy developer will be acquired by investment firms Carlyle Group and SK Capital for a fraction of ...
There is a catch. If the private equity firms can boost sales of bluebird’s three gene therapies to $600 million—over any ...
When the transaction is complete, Bluebird shares will no longer be publicly traded. Pfizer’s Gene Therapy Pullback Continues With Termination of Beqvez Bluebird Bio isn’t the only company ...
Somerville gene therapy company bluebird bio, once among the highest-profile biotechs in the Boston area, has agreed to be ...
Bluebird Bio announced Friday it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK ...
In recent financial reports submitted to the Securities and Exchange Committee (SEC) in an 8-K filing, bluebird bio, Inc. (NASDAQ: BLUE), a leading biotech company, has provided an update on their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback